TIME TO MARKET AND PRICE COMPARISON FOR BIOSIMILAR DRUGS IN EU5

被引：0
|
作者：
Lopez, N. [1 ]
Prada, M. [2 ]
Berard, I [3 ]
Schleich, W. [4 ]
Melson, C. [5 ]
机构：
[1] Oblikue Consulting SL, Barcelona, Spain
[2] Intexo, Rome, Italy
[3] NEXTEP, Paris, France
[4] MArS Market Access & Pricing Strategy GmbH, Ansbach, Germany
[5] Decideum Ltd, London, England
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.09.1111
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PHP217
引用
收藏
页码：S186 / S187
页数：3
相关论文
共 50 条
  • [31] COMPARISON OF PATIENT ACTIVATION LEVELS ACROSS VARIOUS CONDITIONS IN THE US AND EU5
    Annunziata, K.
    Sternbach, N.
    Carpinella, C. M.
    Chapnick, J.
    Patel, P.
    McDonald, M.
    McElwee, N.
    VALUE IN HEALTH, 2018, 21 : S140 - S140
  • [32] EXPERIENCES WITH PRICE COMPETITION OF BIOSIMILAR DRUGS IN HUNGARY
    Homyak, L.
    Nagy, Z.
    Talos, Z.
    Endrei, D.
    Agoston, I
    Csakvari, T.
    Boncz, I
    VALUE IN HEALTH, 2017, 20 (09) : A461 - A461
  • [33] EXPERIENCES WITH PRICE COMPETITION OF BIOSIMILAR DRUGS IN HUNGARY
    Hornyak, L.
    Nagy, Z.
    Talos, Z.
    Agoston, I
    Endrei, D.
    Csakvari, T.
    Boncz, I
    VALUE IN HEALTH, 2014, 17 (07) : A418 - A418
  • [34] PRICING PRESSURES AND MARKET ACCESS OUTCOMES OF ADVANCED THERAPY MEDICINAL PRODUCTS (ATMPS) IN THE EU5
    Jenkins, M. J.
    Borga, P.
    Ribeiro, A.
    VALUE IN HEALTH, 2017, 20 (09) : A663 - A663
  • [35] Market approval for drugs in the EU: time to change direction?
    Curto, Alessandro
    van de Vooren, Katelijne
    Garattini, Livio
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2017, 18 (08): : 933 - 936
  • [36] Market approval for drugs in the EU: time to change direction?
    Alessandro Curto
    Katelijne van de Vooren
    Livio Garattini
    The European Journal of Health Economics, 2017, 18 : 933 - 936
  • [37] UTILITY OF REAL WORLD EVIDENCE DATA TO SUPPORT MARKET ACCESS OF RARE ONCOLOGY INDICATIONS IN EU5
    Kumar, P.
    VALUE IN HEALTH, 2019, 22 : S857 - S857
  • [38] EPIDEMIOLOGY AND TREATMENT OF SOFT TISSUE SARCOMA IN THE EU5
    Robinson, D.
    Nersesyan, K.
    Pomerantz, D.
    VALUE IN HEALTH, 2015, 18 (07) : A439 - A439
  • [39] CRITICAL ASSESSMENT OF ATMP MARKET ACCESS OUTCOMES ON A NATIONAL-LEVEL ACROSS EU5 COUNTRIES
    Jones-Phillips, D. L.
    Bradshaw, S. E.
    VALUE IN HEALTH, 2017, 20 (09) : A565 - A565
  • [40] EXPLORING BIOSIMILAR MARKET ACCESS CONSIDERATIONS ACROSS THE EU
    Walker, L.
    Hewitt, C.
    Craddy, P.
    Foxon, G.
    VALUE IN HEALTH, 2018, 21 : S204 - S204
12345